Quarterly report pursuant to Section 13 or 15(d)

Warrants (Tables)

v3.19.1
Warrants (Tables)
3 Months Ended
Mar. 31, 2019
Warrants And Rights Note Disclosure [Abstract]  
Summary of Warrant Activity A summary of warrant activity for the year ended December 31, 2018 and the three months ended March 31, 2019 is as follows:

 

 

Warrants

 

 

Weighted

Average

Price

 

Balance - December 31, 2017

 

 

2,177,425

 

 

$

3.10

 

Granted

 

 

14,700,000

 

 

 

1.00

 

Exercised

 

 

(9,505,500

)

 

 

1.00

 

Expired

 

 

 

 

 

 

Balance - December 31, 2018

 

 

7,371,925

 

 

 

1.74

 

Granted

 

 

19,166,668

 

 

 

0.83

 

Exercised

 

 

 

 

 

 

Expired

 

 

 

 

 

 

Balance - March 31, 2019

 

 

26,538,593

 

 

$

1.08

 

Summary of Warrants Outstanding

The warrants outstanding as of March 31, 2019 are as follows:

 

 

 

Exercise Price

 

 

Warrants

Outstanding

 

 

Expiration

Date

 

 

$

3.10

 

 

 

48,387

 

 

9/19/2022

 

 

$

2.00

 

 

 

900,000

 

 

4/10/2023

 

 

$

3.10

 

 

 

462,106

 

 

5/10/2024

 

 

$

3.10

 

 

 

602,414

 

 

7/25/2024

 

 

$

3.10

 

 

 

1,064,518

 

 

11/8/2024

 

 

$

1.00

 

 

 

4,294,500

 

 

7/17/2025

 

 

$

0.75

 

 

 

9,583,334

 

 

*

 

 

$

0.90

 

 

 

9,583,334

 

 

3/25/2024

 

 

 

 

 

 

 

26,538,593

 

 

 

 

 

 

 

 

 

 

 

 

 

 

* The earlier of (1) the eighteen-month anniversary of the date of issuance and (2) twenty-one trading days following the Company’s release of top-line data related to its Phase 2 double blind, placebo controlled clinical trial of AG013.